POLR2A突变是小脑脑桥角脑膜瘤的不良预后标志物
该回顾性研究分析70例世界卫生组织I级小脑脑桥角脑膜瘤患者,采用Sanger测序和微卫星阵列检测NF2、AKT1、KLF4、SMO、POLR2A突变及22q缺失。结果显示POLR2A突变与复发风险升高相关(P=.03,HR 9.38,95%CI 1.26-70.0),次全切除亦为复发不良因素(P=5.1×10^-4,HR 63.1,95%CI 6.09-655.0)。
要点
- POLR2A突变患者脑膜内皮型比例更高(P=6.9×10^-4),复发率更高(P=.04)。
- POLR2A突变与复发相关(P=.03,HR 9.38,95%CI 1.26-70.0),次全切除与复发相关(P=5.1×10^-4,HR 63.1,95%CI 6.09-655.0)。
- 次全切除组中POLR2A突变仍为复发不良因素(P=.03,HR 11.1,95%CI 1.19-103.7)。
核心结论
- POLR2A突变和次全切除是小脑脑桥角脑膜瘤复发的的不良预后标志物。
- 对于接受次全切除的小脑脑桥角脑膜瘤病例,仅POLR2A突变是不良预后因素。
- 检测POLR2A突变可能是一种成本效益高、简便且有用的预后判断标志物。
研究设计与样本
- 回顾性分析70例世界卫生组织I级小脑脑桥角脑膜瘤患者的临床数据。
- 采用Sanger测序和微卫星阵列分析体细胞DNA,检测NF2、AKT1、KLF4、SMO、POLR2A突变及22q缺失。
- 分析遗传和临床参数以识别与肿瘤复发相关的因素。
主要发现
- POLR2A突变病例较无POLR2A突变病例脑膜内皮型更多(P=6.9×10^-4),复发率更高(P=.04)。
- 与复发相关的不良预后因素为POLR2A突变(P=.03,HR 9.38,95%CI 1.26-70.0)和次全切除(P=5.1×10^-4,HR 63.1,95%CI 6.09-655.0)。
- 在次全切除组中,POLR2A突变是与肿瘤复发相关的不良预后因素(P=.03,HR 11.1,95%CI 1.19-103.7)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Recent molecular analyses have shown that the driver genetic mutations of meningiomas were associated with the anatomic location. Among these, POLR2A mutation is common among lesions in the skull base, mainly in the cerebellopontine angle (CPA). The objective of this study was to investigate the efficacy of POLR2A mutation as a prognostic marker for CPA meningiomas. METHODS: We retrospectively analyzed the clinical data of 70 patients who had World Health Organization grade I CPA meningiomas. Somatic DNA was analyzed by Sanger sequencing and microsatellite array to examine for NF2 , AKT1 , KLF4 , SMO , and POLR2A mutations and 22q loss. Genetic and clinical parameters were analyzed to identify the factors related with tumor recurrence. RESULTS: We detected clearly the clinical features of the CPA cases with POLR2A mutation. Compared with cases without POLR2A mutation, cases with POLR2A mutation had more meningothelial type ( P = 6.9 × 10 -4 ), and higher rate of recurrence ( P = .04). We found that the poor prognostic factors associated with the recurrence of CPA meningiomas were POLR2A mutation ( P = .03, hazard ratio [HR] 9.38, 95% CI 1.26-70.0) and subtotal resection (STR) ( P = 5.1 × 10 -4 , HR 63.1, 95% CI 6.09-655.0). In addition, in the group that underwent STR, POLR2A mutation was a poor prognostic factor associated with tumor recurrence ( P = .03, HR 11.1, 95% CI 1.19-103.7). CONCLUSION: POLR2A mutation and STR were the poor prognostic markers associated with the recurrence of CPA meningioma. For CPA meningioma cases that underwent STR, only POLR2A mutation was a poor prognostic factor. Detecting POLR2A mutation may be a cost-effective, easy, and useful marker for prognostication.
引用
- Okano A, Miyawaki S, Teranishi Y, et al. POLR2A Mutation is a Poor Prognostic Marker of Cerebellopontine Angle Meningioma. Neurosurgery. 2024. PMID: 38380947. doi:10.1227/neu.0000000000002873
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。